Elevance Health Q4 EPS Forecast Decreased by Zacks Research

Elevance Health, Inc. (NYSE:ELV - Free Report) - Stock analysts at Zacks Research reduced their Q4 2025 earnings per share estimates for shares of Elevance Health in a research report issued on Monday, May 5th. Zacks Research analyst K. Dey now forecasts that the company will earn $4.47 per share for the quarter, down from their prior estimate of $5.31. The consensus estimate for Elevance Health's current full-year earnings is $33.96 per share. Zacks Research also issued estimates for Elevance Health's Q1 2026 earnings at $12.18 EPS, Q2 2026 earnings at $11.67 EPS, Q3 2026 earnings at $9.71 EPS, Q4 2026 earnings at $5.22 EPS and FY2027 earnings at $43.76 EPS.

Elevance Health (NYSE:ELV - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The company reported $11.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.60 by $1.37. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%. The firm had revenue of $48.77 billion for the quarter, compared to the consensus estimate of $46.26 billion.

Other analysts have also recently issued research reports about the company. Truist Financial raised their target price on Elevance Health from $480.00 to $510.00 and gave the stock a "buy" rating in a research report on Friday, April 11th. Mizuho raised their price objective on Elevance Health from $455.00 to $505.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 9th. Royal Bank of Canada reiterated an "outperform" rating and issued a $478.00 target price on shares of Elevance Health in a report on Wednesday, April 23rd. Robert W. Baird restated a "neutral" rating and set a $529.00 price target (down from $625.00) on shares of Elevance Health in a report on Tuesday, April 15th. Finally, Stephens downgraded shares of Elevance Health from an "overweight" rating to an "equal weight" rating and lowered their price objective for the company from $520.00 to $440.00 in a research report on Wednesday, January 22nd. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $510.38.

Elevance Health Trading Up 0.9 %

NYSE ELV opened at $417.80 on Thursday. The firm's 50 day moving average price is $423.65 and its two-hundred day moving average price is $404.75. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.50 and a current ratio of 1.45. Elevance Health has a twelve month low of $362.21 and a twelve month high of $567.26. The stock has a market cap of $94.40 billion, a price-to-earnings ratio of 16.31, a PEG ratio of 1.18 and a beta of 0.66.

Institutional Trading of Elevance Health

Hedge funds and other institutional investors have recently modified their holdings of the stock. Harvest Fund Management Co. Ltd acquired a new stake in shares of Elevance Health in the 1st quarter valued at $579,000. S&CO Inc. acquired a new stake in Elevance Health in the first quarter worth about $839,000. Banque Cantonale Vaudoise bought a new stake in Elevance Health during the 1st quarter worth about $4,098,000. High Ground Investment Management LLP boosted its stake in shares of Elevance Health by 6.2% in the 1st quarter. High Ground Investment Management LLP now owns 222,030 shares of the company's stock valued at $96,574,000 after purchasing an additional 13,020 shares during the last quarter. Finally, Geneos Wealth Management Inc. grew its position in shares of Elevance Health by 41.2% during the 1st quarter. Geneos Wealth Management Inc. now owns 32,932 shares of the company's stock worth $14,324,000 after buying an additional 9,610 shares during the period. Institutional investors and hedge funds own 89.24% of the company's stock.

Insider Buying and Selling at Elevance Health

In other news, CFO Mark Kaye sold 4,588 shares of the stock in a transaction that occurred on Thursday, April 24th. The stock was sold at an average price of $424.82, for a total value of $1,949,074.16. Following the completion of the transaction, the chief financial officer now directly owns 18,977 shares of the company's stock, valued at approximately $8,061,809.14. This represents a 19.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Ronald W. Penczek sold 443 shares of the company's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $415.13, for a total transaction of $183,902.59. Following the completion of the sale, the chief accounting officer now directly owns 1,847 shares in the company, valued at approximately $766,745.11. The trade was a 19.34 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 8,535 shares of company stock valued at $3,521,612 in the last 90 days. 0.29% of the stock is currently owned by insiders.

Elevance Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 25th. Stockholders of record on Tuesday, June 10th will be given a $1.71 dividend. This represents a $6.84 annualized dividend and a dividend yield of 1.64%. The ex-dividend date of this dividend is Tuesday, June 10th. Elevance Health's dividend payout ratio is currently 26.69%.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.